

Special Issue

Recent Advances in Ruminant Vaccines

Message from the Guest Editor

We are pleased to invite you to contribute to this Special Issue titled "Recent Advances in Ruminant Vaccines".

This Special Issue aims to encompass both fundamental research and applied science. It aligns with the journal's scope by addressing topics in veterinary immunology, infectious diseases, biotechnology, and animal health management. To that end, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- Development of new vaccines against bacterial, viral, parasitic, or emerging diseases in ruminants;
- Advances in vaccine delivery systems and adjuvant technologies;
- Evaluation of vaccine efficacy, safety, and immune response in ruminants;
- Field studies on vaccine application and disease control programs;
- Novel strategies for mucosal, oral, or needle-free vaccination;
- Genomic and proteomic approaches in vaccine development;
- Impact of vaccination on antimicrobial use and resistance in ruminant farming;
- Regulatory and practical challenges in vaccine deployment.

We look forward to receiving your valuable contributions to this Special Issue, and to promoting collaborative advances in this crucial field.

Guest Editor

Dr. Petr Slama

Department of Animal Morphology, Physiology and Genetics, Faculty of AgriSciences, Mendel University in Brno, Zemedelska 1, 61300 Brno, Czech Republic

Deadline for manuscript submissions

28 February 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/238675

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).